Planned Solutions Inc. Sells 1,150 Shares of Sanofi (NASDAQ:SNY)

Planned Solutions Inc. trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 18.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,068 shares of the company’s stock after selling 1,150 shares during the quarter. Planned Solutions Inc.’s holdings in Sanofi were worth $244,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of SNY. Stablepoint Partners LLC grew its position in shares of Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares during the period. PDS Planning Inc lifted its stake in Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares during the last quarter. Eagle Ridge Investment Management grew its holdings in Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after purchasing an additional 203 shares during the period. Financial Advocates Investment Management increased its position in Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC raised its stake in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after buying an additional 210 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Up 1.9 %

SNY opened at $51.69 on Wednesday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a market cap of $131.18 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average of $48.46 and a 200 day moving average of $52.15.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period last year, the company earned $2.55 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, sell-side analysts expect that Sanofi will post 3.92 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.